We are live on ! Find out more
27.22 USD
-0.70
2.51%
At close Updated Nov 17, 4:00 PM EST
Pre-market
After hours
27.22
0.00
0%
1 day
-2.51%
5 days
-2.82%
1 month
36.99%
3 months
10.02%
6 months
7.8%
Year to date
2.68%
1 year
-3.82%
5 years
-69.22%
10 years
-56.92%
 

About: Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.

Employees: 7,802

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 33.3%
Neutral 61.1%
Negative 5.6%
Neutral
GlobeNewsWire
5 days ago
Enovis to Present at the Annual Jefferies Global Healthcare Concerence in London
Dallas, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced that members of the Enovis management team will be presenting at the Annual Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT (6:30 a.m. ET).
Enovis to Present at the Annual Jefferies Global Healthcare Concerence in London
Positive
MarketBeat
11 days ago
What Enovis (ENOV) Said on Its Q3 Earnings Call
Enovis NYSE: ENOV reported third-quarter sales of $559 million and raised its full-year adjusted earnings outlook, as growth in its reconstructive business and improved cash generation helped offset what executives described as a volatile market for medical procedures.
What Enovis (ENOV) Said on Its Q3 Earnings Call
Neutral
Seeking Alpha
11 days ago
Enovis Corporation (ENOV) Q3 2026 Earnings Call Transcript
Enovis Corporation ( ENOV ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Kyle Rose - Vice President of Investor Relations Damien McDonald - CEO & Director Phillip Berry - Senior VP & CFO Conference Call Participants Iseult McMahon - BTIG, LLC, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Ross Osborn - Wells Fargo Securities, LLC, Research Division Young Li - Jefferies LLC, Research Division Vikramjeet Chopra - BMO Capital Markets Equity Research Steven Lichtman - William Blair & Company L.L.C.
Enovis Corporation (ENOV) Q3 2026 Earnings Call Transcript
Positive
Zacks Investment Research
12 days ago
Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates
Enovis (ENOV) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.75 per share a year ago.
Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates
Neutral
GlobeNewsWire
12 days ago
ENOVIS Announces Third Quarter 2026 Results
Dallas, TX, Nov. 05, 2026 (GLOBE NEWSWIRE) -- - Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 2, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
ENOVIS Announces Third Quarter 2026 Results
Neutral
GlobeNewsWire
1 month ago
Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
Dallas, TX, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2026 financial results on Thursday, November 5th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning.
Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
Neutral
PRNewsWire
1 month ago
Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
Company expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry ROSEMONT, Ill., Sept. 22, 2026 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced that Enovis ™ has expanded its support of the AAOS Registry Program, becoming the first industry partner to sponsor multiple AAOS registries.
Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
Neutral
The Motley Fool
2 months ago
Insider at Medical Device Maker Buys More Than 7,500 Shares
The acquisition involved 7,598 shares at a weighted average price of $19.74 per share, representing a total investment of ~$150,000. The transaction size equals 14% of the equity stake held by the executive before the filing.
Insider at Medical Device Maker Buys More Than 7,500 Shares
Positive
Zacks Investment Research
2 months ago
What Makes Enovis (ENOV) a New Buy Stock
Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Enovis (ENOV) a New Buy Stock
Negative
Zacks Investment Research
2 months ago
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Price charts implemented using Lightweight Charts™